diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md
index bc61445b..c47f7a1a 100644
--- a/pages/InCORNTD 2025___Application.md	
+++ b/pages/InCORNTD 2025___Application.md	
@@ -3,5 +3,5 @@
 	- **Description**: The fixed-dose coformulation of albendazole and ivermectin is the result of 10+ years of innovations carried out by African and European organizations working through public-private partnerships. 
 	  This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a pivotal trial, although its potential uses go beyond these parasites.
 	  The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing better efficacy against more species of helminths.
-	  While the frequently used albendazole 400mg monotherapy
+	  While the frequently used albendazole 400mg monotherapy barely manages to reduce the prevalence of *Trichuris trichiura*, combining it with ivermectin
 -
\ No newline at end of file